Zobrazeno 1 - 10
of 1 485
pro vyhledávání: ''
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Christian Lang, Felix Egger, Mir Alireza Hoda, Alessandro Saeed Querner, Bence Ferencz, Victor Lungu, Robert Szegedi, Levente Bogyo, Klara Torok, Felicitas Oberndorfer, Thomas Klikovits, Anna Schwendenwein, Kristiina Boettiger, Ferenc Renyi-Vamos, Konrad Hoetzenecker, Karin Schelch, Zsolt Megyesfalvi, Balazs Dome
Publikováno v:
Lung Cancer. 169:40-46
The prognostic value of lymphocyte-to-monocyte ratio (LMR) has already been evaluated in a wide range of malignancies including patients with non-surgically managed small cell lung cancer (SCLC). However, the impact of LMR on survival in surgically t
Autor:
Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano
Publikováno v:
Lung Cancer. 166:221-227
Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters.Baseline clinical and laborato
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
Didier, Debieuvre, Charles, Dayen, Adrien, Dixmier, David, Pau, Anna, Sibley-Revelat, William, Greenwood, Samuel, Gally, Lionel, Falchero
Publikováno v:
Lung Cancer. 164:1-7
FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival.A target population of f
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Marie Dagonnier, Nathalie Nagy, Valérie Durieux, Vito Tota, Laure Binet, Marie Diaz, Stéphane Holbrechts, Jose-Antonio Elosegi, Didier Wery
Publikováno v:
Lung cancer, 160
Immune checkpoint inhibitors (ICI) improve the prognosis of patients with advanced non-small cell lung cancer. However, clinicians should be aware of potentially life-threatening immune-related adverse events (irAEs). We report a case of a 67-year-ol
Publikováno v:
Lung Cancer
Objectives Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinica